Anti-PD-L1 immunotherapy inhibits the progression of sorafenib acquired resistant hepatocellular carcinoma by inducing immune activation

被引：0
|
作者：
Xu, D. [1 ]
Zhu, Y. [1 ]
Yang, J. [1 ]
Zhang, Z. [1 ]
Li, T. [1 ]
Yang, J. [1 ]
Dong, Q. [1 ,2 ]
Qin, L. [1 ,2 ]
机构：
[1] Fudan Univ, Canc Metastasis Inst, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2019年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P1104
引用
收藏
页码：1748 / 1749
页数：2
相关论文
共 50 条
  • [1] IMMUNOTHERAPY Benefit with anti-PD-L1
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (02) : 70 - 70
  • [2] The Curative Effect of Cryptotanshinone and anti-PD-L1 on Mouse Hepatocellular Carcinoma
    Han, Zhen
    Liu, Shuo
    Lin, Hongsheng
    Trivett, Anna
    Yang, De
    Oppenheim, Joost J.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [3] Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma
    Chiang, I-Tsang
    Lee, Yuan-Hao
    Tan, Zhao-Lin
    Hsu, Fei-Ting
    Tu, Hsi-Feng
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 147
  • [4] Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy
    Ludwig, Nils
    Wieteska, Lukasz
    Hinck, Cynthia S.
    Yerneni, Saigopalakrishna S.
    Azambuja, Juliana H.
    Bauer, Richard J.
    Reichert, Torsten E.
    Hinck, Andrew P.
    Whiteside, Theresa L.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (06) : 1102 - 1111
  • [5] Berberine in combination with anti-PD-L1 suppresses hepatocellular carcinoma progression and metastasis via Erk signaling pathway
    Miao, Ganggang
    Zhang, Zhiyu
    Wang, Meiyan
    Gu, Xingwei
    Xiang, Dongxiao
    Cao, Hongyong
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (01): : 103 - 112
  • [6] Combination of transcatheter arterial chemoembolization and anti-PD-L1 liposomes therapy suppressed hepatocellular carcinoma progression in mice
    Li, Jie
    Zhang, Lijuan
    Tao, Yun
    Sun, Zongqiong
    Ge, Yuxi
    Hu, Shudong
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 189
  • [7] Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment
    Li, Huawei
    You, Jia
    Wei, Yuanfeng
    Zheng, Lingnan
    Yang, Ju
    Xu, Jingyi
    Li, Yue
    Li, Zhaojun
    Yang, Xi
    Yi, Cheng
    PHYTOMEDICINE, 2024, 123
  • [8] Prevotellaceae Modulates Colorectal Cancer Immune Microenvironment to Assist Anti-PD-L1 Immunotherapy
    Xu, Song
    Kong, Jianqiao
    Dai, Yang
    Li, Hengping
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2024, 35 (12):
  • [9] Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma
    Netto, George J.
    LANCET, 2016, 387 (10031): : 1881 - 1882
  • [10] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
12345